Pfizer Corporation

Paul Andrew Dasilva-Jardine

Bruce A Lefker

Philip Albert Carpino

John Anthony Ragan

Kimberly O Cameron

Jerry Anthony Murry

Willard M Welch, Jr

Angel Guzman-Perez

Ravi Shanker Garigipati

Kevin K Liu

Michael Paul Zawistoski

Phoebe Chiang

Robert F Day

William A Novomisle

Richard Chesworth

Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HTreceptors in animals are described herein

5-HT receptor ligands and uses thereof

This invention relates to compounds useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, and to pharmaceutical composition, methods, and kits comprising such compounds.

Tetrahydroisoquinoline compounds as estrogen agonists/antagonists

This application relates to processes for making compounds of formula I, and processes for making intermediates useful in the processes for making compounds of formula I.

Tartrate salt of a substituted dipeptide as growth hormone secretagogue

This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Prostaglandin agonists

Growth-hormone secretagogues

This invention is directed to compounds of the formula

Method of treatment using certain growth-hormone secret agogues

This invention is directed to the (L)-tartaric acid salt of 2-amino-N-&lcub;1-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-&lsqb;3-oxo-3a-pyridin-2-ylmethyl-2-(2,2,2-trifluoro-ethyl)-2,3,3a,4,6,7-hexahydro-pyrazolo&lcub;4,3-c&rcub;pyridin-5-yl&rsqb;-ethyl&rsqb;-2-methyl-propionamide which is a growth hormone secretagogue and as such is useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compound. The (L)-tartaric acid salt of the compound of this invention is useful in the treatment and/or prevention of osteoporosis, insulin resistance and other conditions or diseases associated with growth hormone deficiency. The (L)-tartaric acid salt of the compound of the present invention is also useful in treating osteoporosis when used in combination with: a bisphosphonate compound; estrogen, Premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin. Further, the present invention is directed to pharmaceutical compositions. This invention is further directed to methods comprising administering to a human or other animal a combination of an alpha-2 adrenergic agonist and the (L)-tartaric acid salt of the compound of this invention.

Growing community of inventors

Providence, RI, United States of America

Paul Andrew Dasilva-Jardine